Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No increased cancer risk after Viracept contamination

This article was originally published in Scrip

Executive Summary

Batches of Roche's HIV protease inhibitor Viracept (nelfinavir) contaminated with ethyl mesilate did not increase the risk of cancer developing in patients who took them, the European Medicines Agencyhas confirmed after reviewing toxicology studies. The European Commission suspended the product's marketing authorisation last June but the suspension was lifted in October when the problems at a Swiss manufacturing plant that led to the contamination had been resolved (Scrip Online, September 21st, 2007).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts